TNG908
MTAP-deleted solid tumors (e.g., NSCLC, pancreatic cancer, glioblastoma)
Key Facts
Indication
MTAP-deleted solid tumors (e.g., NSCLC, pancreatic cancer, glioblastoma)
Phase
Phase 1/2
Status
Active
Company
About Tango Therapeutics
Tango Therapeutics is a public biotechnology company developing next-generation targeted cancer therapies based on the principle of synthetic lethality. The company's discovery platform integrates CRISPR-based functional genomics and computational biology to identify novel drug targets in genetically defined patient populations. Tango's pipeline includes multiple programs targeting tumor suppressor gene loss, with its lead programs in clinical development. The company is strategically positioned to address significant unmet needs in precision oncology.
View full company profile